Across TCGA pan-cancer cohorts, LINC02630 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of LINC02630’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where LINC02630 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC02630 is over-expressed in tumor, although a few such as BRCA and COAD show the opposite, repressed pattern.

BRCA, UCEC, and KIRC are the cancer types where LINC02630 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC02630 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	All	−0.068	<.001	6	view →
UCEC	All	IV	+0.230	.016	2	view →
KIRC	All	III,IV	+0.017	.029	2	view →
COAD	All	All	−0.011	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: LINC02630 RNA expression & survival · all LINC02630 data types